ISSN 1178-6191

Maori Health Review

Making Education Easy Issue 117 – 2025

Maori Health Review

Improving lung cancer survival outcomes for Māori

Authors: Gurney J et al.

Summary: A nationwide project has identified a number of disparities along the lung cancer treatment pathway between Māori and non-Māori. The project reviewed lung cancer registrations on the New Zealand Cancer Registry over the period 2007 to 2019 and linked these to hospital, emergency department and outpatient records, as well as other datasets. Positive findings included equitable access to bronchoscopy, pathological diagnosis, radiation therapy and systemic therapy, as well as minimal differences in the timing of treatment between ethnic groups. Disparities for Māori compared with non-Māori included higher emergency presentation rates, poorer access to early detection, lower surgery rates and longer distances required to travel for bronchoscopy, surgery and radiation therapy. Five recommendations for action were made, with a view towards improving survival outcomes for Māori: 1) shift lung cancer diagnoses away from emergency rooms to primary care and/or screening contexts; 2) ensure that Māori who are good candidates for surgery are offered this treatment; 3) reduce the treatment travel burden on Māori with lung cancer; 4) make the lung cancer treatment pathway acceptable to Māori; 5) improve the quality and completeness of national health data collections.

Comment: I found some of the language used here a little confronting (I’m not convinced about causes for “celebration”, even when cautious). However, the five recommendations are brilliant, and provide excellent starting points for the health system to work on – which I hope it will do.

Reference: N Z Med J. 2025 Jul;138(1618):96-103.

Abstract

Privacy Policy: Research Review will record your email details on a secure database and will not release them to anyone without your prior approval. Research Review and you have the right to inspect, update or delete your details at any time. The views expressed in this Publication are personal to the authors, and do not necessarily represent the views or policy of the Ministry of Health on the issues dealt with in the publication.

Disclaimer: This publication is not intended as a replacement for regular medical education but to assist in the process. The reviews are a summarised interpretation of the published study and reflect the opinion of the writer rather than those of the research group or scientific journal. It is suggested readers review the full trial data before forming a final conclusion on its merits.

Research Review publications are intended for New Zealand health professionals.

Systemic anti-cancer treatment for Māori with stage III and IV non-small cell lung cancer in Aotearoa New Zealand

Authors: Tu’akoi K et al.

Summary: Māori with advanced non-small cell lung cancer are less likely to receive first line targeted therapy compared with non-Māori, according to a cohort study of patients in the New Zealand Midland Region between January 2011 and December 2021. The study included 2549 patients, of whom 775 (30%) were Māori. There was no difference between Māori and non-Māori in the overall rate of systemic anticancer therapy use. However, Māori were less likely to receive targeted therapy in the first-line setting (8.5% of patients vs 16.1% of non-Māori patients; p<0.01). Māori also had higher cancer-specific mortality (adjusted odds ratio 1.19; 95% confidence interval [CI] 1.08-1.32; p<0.001).

Comment: This is much-needed research given the higher rates of lung cancer among Māori and importance of timely treatment. At first glance, the finding of similar overall systemic anticancer therapy use for Māori and non-Māori may appear reassuring. However, this masks a critical inequity: Māori were significantly less likely to receive f irst-line targeted therapy, despite clear evidence of its survival benefits. The authors raise important questions about Māori experiences in diagnostic pathways, access to genomic testing, clinical decision-making, and funding and the systemic factors that may play roles.

Reference: N Z Med J. 2025 Jul;138(1618):15-29.

Abstract

Child and adolescent/young adult cancer incidence and survival for Māori in Aotearoa New Zealand

Authors: Gurney J et al.

Summary: A review of cancer diagnoses between 2007 and 2019 among individuals aged <25 years found differences between Māori and Europeans in incident cancers and survival. Data were extracted from the New Zealand Cancer Registry. Māori were more likely to be diagnosed with poor-prognosis cancers, such as brain cancer, and less likely to be diagnosed with good-prognosis cancers, such as Hodgkin’s lymphoma and melanoma. Māori were less likely to survive cancer even after adjusting for differences in cancer type. The study authors noted that further quantitative and qualitative research could inform actions aimed at addressing disparities and improving survival for Māori.

Comment: Again, important that we monitor cancer types, rates and mortality by ethnicity. As the authors note, kaupapa Māori approaches to future research, and co-design with Māori in the design of interventions, are needed to ensure equity focused action and outcomes.

Reference: Cancer Epidemiol. 2025 Aug;97:102868.

Abstract

Maori Health Review
Maori Health Review

Vaping cessation strategies and triggers for relapse amongst people from New Zealand who have vaped

Authors: Rahimi M et al.

Summary: A web-based survey conducted in December 2022 has revealed that reasons for quitting and returning to vaping are similar to those for smoking. Participants (n=1119) in the survey were aged ≥16 years; 144 had never smoked, 975 used to smoke, 401 currently vaped nicotine, and 718 used to vape nicotine. Most participants were aged ≥25 years (89%), 63% were female, and 21% were Māori and/or Pacific. Smoking or vaping for ≥2 years and vaping >3% nicotine were predictors of vaping dependence. Health concerns, disliking feeling dependent and cost were cited as reasons for trying to quit vaping. Stopping abruptly, nicotine tapering and family/friend support were strategies used to quit. Stress, being around others who vaped and nicotine withdrawal were cited as triggers for relapse. The study authors concluded that strategies used to support vaping cessation can be similar to strategies used for smoking cessation.

Comment: Having noted the evidence about the inequitable uptake of vaping in Aotearoa, I’m now pleased to add this evidence about strategies to support cessation and prevent relapse for people who vape.

Reference: Drug Alcohol Rev. 2025 Jul;44(5):1394-1411.

Abstract

Comparison of the incidence and risk factors of acute respiratory illness associated with COVID-19 and influenza

Authors: Huang QS et al., on behalf of the SHIVERS investigation team

Summary: Vaccination, age, ethnicity, and household size are independent protective/ risk factors for COVID-19 and influenza in New Zealand, according to results of the SHIVERS II, III and IV Prospective Community Cohort Study. Over the period 7 February to 2 October 2022, the adjusted cumulative incidence for COVID-19 in Wellington was 4.5 times higher than for influenza. For COVID-19, the highest incidence was seen in adolescents aged 12-17 years and individuals of European/other ethnicity. For influenza, the highest incidence was seen in children aged 1-4 years and Māori. Risk of COVID-19 infection was 75% higher in adolescents who had received two doses of the COVID-19 vaccine vs adults who had received three doses. Individuals with COVID-19 were less likely to access health care or experience febrile and severe illness than those with influenza, but were more likely to report sore throat, headache, myalgia, and loss of taste or smell.

Reference: J Infect Dis. 2025 Aug;232(2):450-464.

Abstract

The burden of HMPV- and influenza-associated hospitalizations in adults in New Zealand before and after the COVID-19 pandemic

Authors: Aminisani N et al.

Summary: A surveillance study of adults (aged ≥20 years) hospitalised with acute respiratory infections in Auckland between 2012 and 2023 found that those aged ≥80 years, of Māori or Pacific ethnicity, and living in low socioeconomic status areas had the highest hospitalisation rates for both influenza and human metapneumovirus (HMPV). Crude hospitalisation rates were 9.7 per 100 000 adults (95% CI 9.0-10.4) for HMPV and 48.2 (95% CI 46.6-49.7) for influenza. HMPV-associated hospitalisation rates were not significantly different before and after the COVID-19 pandemic, but influenza-associated hospitalisation increased from 43.0 per 100 000 adults before the pandemic, to 54.4 in 2022 and 79.5 in 2023.

Reference: J Infect Dis. 2025 Jul;232(Supplement_1):S47-S58.

Abstract

Variation in clinical presentation, complications and outcomes for Māori and Pacific peoples among hospitalised adults with COVID-19 in 2022

Authors: Maze MJ et al.

Summary: Among adults (≥16 years) hospitalised with COVID-19 at 11 New Zealand hospitals between January and May 2022, Māori and Pacific individuals were younger at presentation, and had a lower vaccination rate and a higher risk of complications than non-Māori, non-Pacific (NMNP) individuals. Median age was 52, 57 and 63 years for Māori, Pacific and NMNP individuals, respectively. Corresponding rates of vaccination (≥2 doses) were 73.4%, 76.7% and 84.8%. Māori had a greater risk of acute kidney injury, cardiac arrhythmia, shock, myocardial infarction, cardiac arrest and acute respiratory distress syndrome compared with NMNP individuals, while Pacific individuals had a greater risk of acute kidney injury and pneumonia, and a lower risk of thromboembolism and myocarditis/pericarditis. There were no differences in age-standardised mortality between ethnic groups.

Comment: As someone working in primary care and seeing so many people unwell with respiratory infections these last few months, with more people requiring hospitalisation than I would have seen 6 years ago, I think these three papers provide several timely reminders. They highlight the importance of monitoring health by ethnicity, of targeted vaccination and other prevention activities and of addressing the wider determinants for respiratory infections for hauora Māori.

Reference: Intern Med J. 2025 Aug;55(8):1339-1349.

Abstract